TY - JOUR
T1 - EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders
T2 - Lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma
AU - Kempf, Werner
AU - Pfaltz, Katrin
AU - Vermeer, Maarten H.
AU - Cozzio, Antonio
AU - Ortiz-Romero, Pablo L.
AU - Bagot, Martine
AU - Olsen, Elise
AU - Kim, Youn H.
AU - Dummer, Reinhard
AU - Pimpinelli, Nicola
AU - Whittaker, Sean
AU - Hodak, Emmilia
AU - Cerroni, Lorenzo
AU - Berti, Emilio
AU - Horwitz, Steve
AU - Prince, H. Miles
AU - Guitart, Joan
AU - Estrach, Teresa
AU - Sanches, José A.
AU - Duvic, Madeleine
AU - Ranki, Annamari
AU - Dreno, Brigitte
AU - Ostheeren-Michaelis, Sonja
AU - Knobler, Robert
AU - Wood, Gary
AU - Willemze, Rein
PY - 2011/10/13
Y1 - 2011/10/13
N2 - Primary cutaneous CD30+ lymphoproliferative disorders (CD30 + LPDs) are the second most common form of cutaneous T-cell lymphomas and include lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma. Despite the anaplastic cytomorphology of tumor cells that suggest an aggressive course, CD30+ LPDs are characterized by an excellent prognosis. Although a broad spectrum of therapeutic strategies has been reported, these have been limited mostly to small retrospective cohort series or case reports, and only very few prospective controlled or multicenter studies have been performed, which results in a low level of evidence for most therapies. The response rates to treatment, recurrence rates, and outcome have not been analyzed in a systematic review. Moreover, international guidelines for staging and treatment of CD30+ LPDs have not yet been presented. Based on a literature analysis and discussions, recommendations were elaborated by a multidisciplinary expert panel of the Cutaneous Lymphoma Task Force of the European Organization for Research and Treatment of Cancer, the International Society for Cutaneous Lymphomas, and the United States Cutaneous Lymphoma Consortium. The recommendations represent the state-of-the-art management of CD30+ PDs and include definitions for clinical endpoints as well as response criteria for future clinical trials in CD30+ LPDs.
AB - Primary cutaneous CD30+ lymphoproliferative disorders (CD30 + LPDs) are the second most common form of cutaneous T-cell lymphomas and include lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma. Despite the anaplastic cytomorphology of tumor cells that suggest an aggressive course, CD30+ LPDs are characterized by an excellent prognosis. Although a broad spectrum of therapeutic strategies has been reported, these have been limited mostly to small retrospective cohort series or case reports, and only very few prospective controlled or multicenter studies have been performed, which results in a low level of evidence for most therapies. The response rates to treatment, recurrence rates, and outcome have not been analyzed in a systematic review. Moreover, international guidelines for staging and treatment of CD30+ LPDs have not yet been presented. Based on a literature analysis and discussions, recommendations were elaborated by a multidisciplinary expert panel of the Cutaneous Lymphoma Task Force of the European Organization for Research and Treatment of Cancer, the International Society for Cutaneous Lymphomas, and the United States Cutaneous Lymphoma Consortium. The recommendations represent the state-of-the-art management of CD30+ PDs and include definitions for clinical endpoints as well as response criteria for future clinical trials in CD30+ LPDs.
UR - http://www.scopus.com/inward/record.url?scp=80054119243&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=80054119243&partnerID=8YFLogxK
U2 - 10.1182/blood-2011-05-351346
DO - 10.1182/blood-2011-05-351346
M3 - Article
C2 - 21841159
AN - SCOPUS:80054119243
SN - 0006-4971
VL - 118
SP - 4024
EP - 4035
JO - Blood
JF - Blood
IS - 15
ER -